Glenmark to Launch Eribulin Mesylate Injection in U.S. Market

Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd, announced the upcoming launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. The company confirmed distribution will begin in September 2025, marking a significant addition to its institutional portfolio.

Bioequivalence to Halaven® Injection

The newly launched Eribulin Mesylate Injection is bioequivalent and therapeutically equivalent to the reference listed drug Halaven® Injection, 1 mg/2 mL (0.5 mg/mL), marketed by Eisai, Inc. This ensures patients can access a cost-effective and reliable alternative to the branded therapy.

Market Potential

According to IQVIA® sales data for the 12-month period ending July 2025, the Halaven® Injection market—including brand and available therapeutic equivalents—recorded annual sales of approximately $66.3 million. Glenmark’s entry into this segment highlights the company’s strategy of targeting complex generics with strong growth potential.

Strategic Significance

Commenting on the development, Marc Kikuchi, President & Business Head, North America, said, “This launch marks our commitment to expanding our institutional product portfolio and reinforces our mission to provide affordable alternatives for patients in need.” This also represents Glenmark’s first complex generic launch in the U.S., underlining its focus on innovation and market expansion.

Also Read: Glenmark Pharma Revenue Up 0.6% in Q1 FY26 Results!

Conclusion

The launch of Eribulin Mesylate Injection strengthens Glenmark’s U.S. footprint in the oncology and institutional space. With its proven equivalence to Halaven® and a sizeable market opportunity, this move demonstrates Glenmark’s ability to deliver value to patients while driving growth in complex generics.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.